About Avisa Diagnostics Inc Company

Avisa Diagnostics Inc is a clinical-stage medical device company developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community acquired pneumonia, which demonstrated positive safety and clinical efficacy results. Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials.